Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report

BMC Psychiatry

Case Report

Kazuhiko Yamamuro¹  Toshifumi Kishimoto¹  Sohei Kimoto¹  Satoshi Naemura²  Hiroki Matsuura²  Izumi Harada² 

[1] Department of Psychiatry, Nara Medical University School of Medicine, 840 Shijo-cho, 634-8521, Kashihara, Nara, Japan;Department of Psychiatry, Tenri Hospital, Tenri, Japan;

关键词: Schizoaffective disorder;    Schizophrenia;    Paliperidone extended-release;    Neutropenia;    Leukopenia;    Lithium carbonate;    Valproic acid;   

DOI  :  10.1186/s12888-016-0874-x

 received in 2015-09-20, accepted in 2016-05-16,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundAntipsychotic drug treatment can potentially lead to adverse events such as leukopenia and neutropenia. Although these events are rare, they represent serious and life-threatening hematological side effects.Case presentationWe present a case study of a patient with schizoaffective disorder in a 50-year-old woman. We report a case of paliperidone extended-release (ER)-induced leukopenia and neutropenia in a female patient with schizoaffective disorder. Initiating lithium carbonate treatment and decreasing the dose of valproic acid improved the observed leukopenia and neutropenia. This treatment did not influence psychotic symptoms.ConclusionThe combination of paliperidone ER and valproic acid induces increased paliperidone ER plasma levels. Lithium carbonate was successfully used to treat paliperidone ER-induced leukopenia and neutropenia.

【 授权许可】

CC BY   
© Matsuura et al. 2016